Company profile
UK company 11460425, incorporated on 11 July 2018.
Home | 52 North
We create affordable, cutting-edge technology to bring healthcare closer to patients.
Company number 11460425
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
AP01 | Transaction MzU0MTM5NDM5MmFkaXF6a2N4
Published 01 Sep 2026 09:07
RESOLUTIONS | Transaction WUY2WkIwSkdhZGlxemtjeA | Paper/PDF filed
Published 07 Aug 2026 00:55
Company registered at Companies House
1 Jan 2023 to 30 Sep 2024
Neutropenic sepsis (NS) is a life-threatening complication of cancer chemotherapy. It occurs because chemotherapy temporarily suppresses the immune system, particularly neutrophil cells, and even mild illnesses can be fatal for patients during this time. As a result, if any chemotherapy patient has a fever or feels unwell they are advised to attend hospit...
1 Dec 2022 to 31 May 2025
To synthesise new antibodies and develop new cutting-edge lateral flow-based diagnostics to support more precise monitoring of cancer patients at risk of complications from chemotherapy
1 Jan 2020 to 31 Dec 2020
Neutropenic sepsis (NS) is a life-threatening medical emergency that occurs in patients having chemotherapy. NS occurs because chemotherapy may suppress the immune system and if patients develop an infection during this time, even a mild illness can be fatal. Delays to antibiotic use increase the risk of death. The key blood cell that is suppressed and le...
